卒中后二级预防药物的使用与停药模式
基于澳大利亚卒中临床登记库的前瞻性数据,回顾性纳入9,817例首次卒中或TIA成人患者,链接全国药品配药与医保理赔数据。多数患者出院后一年内接受二级预防药物,但约五分之一至三分之一在出院后一年内停药。出院时处方、每季度全科医生接触及专科医生处方与降压药停药风险降低相关。
要点
- 卒中或TIA后多数患者使用二级预防药物,但一年内停药比例达20.9%~34.1%。
- 出院时处方、定期全科随访和专科医生处方与降压药停药风险降低相关。
- 需改善出院后照护以减少不合理的二级预防药物停药。
核心结论
- 卒中或TIA后二级预防药物使用模式不理想,许多幸存者在出院后一年内停药。
- 需要改善卒中或TIA患者出院后照护,以尽量减少不合理的停药。
研究设计与样本
- 回顾性队列研究,使用澳大利亚卒中临床登记库2010年4月至2014年6月首次急性卒中或TIA成人患者的前瞻性数据。
- 数据与全国药品配药及Medicare理赔数据链接,共纳入9,817例首次卒中或TIA成人患者(45.4%女性,47.6%年龄≥75岁,11.4%脑出血)。
- 药物使用者定义为出院后一年内有至少1次配药;停药定义为出院后一年内无药物供应≥90天。
- 采用多变量竞争风险回归(考虑观察期间死亡)分析停药时间相关因素。
主要发现
- 大多数患者接受二级预防药物:降压药79.3%、抗血栓药81.8%、降脂药82.7%。
- 出院后一年内停药比例:降压药20.9%、抗血栓药34.1%、降脂药28.5%。
- 出院时处方(SHR 0.70;95%CI 0.62-0.79)、每季度与全科医生接触(SHR 0.62;95%CI 0.57-0.67)及专科医生处方(SHR 0.87;95%CI 0.77-0.98)均与降压药停药呈负相关。
关键数值与推荐
- 药物使用者定义为出院后一年内有至少1次配药。
- 停药定义为出院后一年内无药物供应≥90天。
- 出院时处方、每季度全科医生接触、专科医生处方与降压药停药的SHR分别为0.70(95%CI 0.62-0.79)、0.62(95%CI 0.57-0.67)、0.87(95%CI 0.77-0.98)。
临床怎么用
- 卒中或TIA患者出院时应确保二级预防药物处方,并安排定期全科随访以降低停药风险。
- 对出院后一年内的二级预防药物使用进行监测,识别并干预不合理停药。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether certain patient, acute care, or primary care factors are associated with medication initiation and discontinuation in the community after stroke or TIA. METHODS: This is a retrospective cohort study using prospective data on adult patients with first-ever acute stroke/TIA from the Australian Stroke Clinical Registry (April 2010 to June 2014), linked with nationwide medication dispensing and Medicare claims data. Medication users were those with ≥1 dispensing in the year postdischarge. Discontinuation was assessed among medication users and defined as having no medication supply for ≥90 days in the year postdischarge. Multivariable competing risks regression, accounting for death during the observation period, was conducted to investigate factors associated with time to medication discontinuation. RESULTS: Among 17,980 registry patients with stroke/TIA, 91.4% were linked to administrative datasets. Of these, 9,817 adults with first-ever stroke/TIA were included (45.4% female, 47.6% aged ≥75 years, and 11.4% intracerebral hemorrhage). While most patients received secondary prevention medications (79.3% antihypertensive, 81.8% antithrombotic, and 82.7% lipid-lowering medication), between one-fifth and one-third discontinued treatment over the subsequent year postdischarge (20.9% antihypertensive, 34.1% antithrombotic, and 28.5% lipid-lowering medications). Prescription at hospital discharge (sub-hazard ratio [SHR] 0.70; 95% confidence interval [CI] 0.62-0.79), quarterly contact with a primary care physician (SHR 0.62; 95% CI 0.57-0.67), and prescription by a specialist physician (SHR 0.87; 95% CI 0.77-0.98) were all inversely associated with antihypertensive discontinuation. CONCLUSIONS: Patterns of use of secondary prevention medications after stroke/TIA are not optimal, with many survivors discontinuing treatment within 1 year postdischarge. Improving postdischarge care for patients with stroke/TIA is needed to minimize unwarranted discontinuation.
引用
- Dalli LL, Kim J, Thrift AG, et al. Patterns of Use and Discontinuation of Secondary Prevention Medications After Stroke. Neurology. 2020. PMID: 33093227. doi:10.1212/WNL.0000000000011083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。